ALK-Positive Anaplastic Large Cell Lymphoma (DBCOND0113476)

Identifiers

Synonyms

ALK+ Anaplastic Large Cell Lymphoma / Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Positive / Large cell anaplastic lymphoma T cell and Null cell type (disorder) / Anaplastic large-cell lymphoma / Anaplastic large cell lymphoma, T cell and Null cell type (morphologic abnormality) / Large cell anaplastic lymphoma (disorder) / Lymphoma, Large-Cell, Anaplastic

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02462538	Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL	Brentuximab vedotin Imatinib	treatment	1 / 2	terminated
NCT04260009	Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors	Brigatinib	treatment	1 / 2	withdrawn
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Tislelizumab	treatment	2	completed
NCT03707847	Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL	Crizotinib Etoposide	treatment	4	unknown_status
NCT04476459	Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL	Camrelizumab Rivoceranib	treatment	1 / 2	unknown_status
NCT04058470	Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	Cyclophosphamide Doxorubicin Prednisone Rituximab Toripalimab Vincristine	treatment	1 / 2	recruiting
NCT04796857	Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL	Lenalidomide Tislelizumab	treatment	1 / 2	unknown_status
NCT05934045	Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma	Aloe vera leaf Ascorbic acid Glycerin Nicotinamide Vitamin A	Not Available	Not Available	active_not_recruiting
NCT06176690	Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas	No drug interventions	treatment	1	not_yet_recruiting
NCT02729961	Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma	Brentuximab vedotin Ceritinib	treatment	1 / 2	withdrawn
NCT04925609	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors	Brigatinib	other	1 / 2	recruiting
NCT02419287	Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas	Crizotinib	treatment	2	completed
NCT03505554	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma	Lorlatinib	treatment	2	recruiting
NCT03603847	Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma	No drug interventions	Not Available	Not Available	completed
NCT03719898	Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma	Brigatinib	treatment	2	withdrawn
NCT03113500	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Beta-D-Glucose Brentuximab vedotin Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Prednisone	treatment	2	active_not_recruiting
NCT01979536	Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma	Beta-D-Glucose Brentuximab vedotin Crizotinib Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Etoposide Ifosfamide Methopterin Methotrexate Tyrosine	treatment	2	completed
NCT05978141	A Registry for People With T-cell Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Nivolumab Talimogene laherparepvec	treatment	2	active_not_recruiting
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Lenalidomide Prednisone Sulfate ion Vincristine	treatment	1 / 2	completed